COVID-19 Therapeutics Available for LTC Provider Onsite Use – Enrollment Required

Long-term care facilities wanting to provide COVID-19 therapeutics must first enroll as a therapeutics provider with DSHS by emailing DSHS Therapeutics or calling Provider Support at 833‑832‑7068, Option 0.

HHSC Long-term Care Regulation is reminding providers about this due to an increase in COVID-19 cases.

Once approved, providers may order directly from the Health Partner Ordering Portal.

Therapeutics Availability and Clinical Considerations

As of May 17, 2020, Texas pharmacies have Paxlovid (ritonavir-boosted nirmatrelvir), which is the first line treatment per the NIH Treatment Guidelines for high-risk patients with symptomatic COVID-19 infection.

Use the HHS Therapeutics Locator to find the nearest pharmacy to your resident with Paxlovid in stock. Staff and residents can also access Federal Test to Treat Sites to receive testing and access to the prescription at the same location.

Additional clinical considerations for Paxlovid  can be found in the NIH Treatment Guidelines section on Paxlovid.

Other options in the NIH treatment Guidelines include:

  • Remdesivir (Veklury).
  • Bebtelovimab.
  • Molnupiravir (Lagevrio).

Remdesivir can be purchased from the distributor for outpatient use. Bebtelovimab and Molnupiravir can also be found on the HHS Therapeutics Locator webpage.

Find additional resources for therapeutics on the DSHS Information for COVID-19 Therapeutics Providers webpage.